SOONER STATE CCOP

更快州CCOP的具体目标是向全州的社区提供NCI批准的临床试验，其中包括癌症治疗和癌症控制研究。长期目标包括：1)增加NCI批准的临床试验在该州未得到充分服务的农村和少数民族人口中的可获得性；2)扩大社区医生在癌症预防和癌症控制项目中的参与；4)增加NCI临床试验的患者收益；5)衡量NCI临床试验的可获得性对该州临床结果的影响。首先，越早的州CCOP是一个单一的组成部分，癌症护理协会公司(CCA)，这是一个私人执业肿瘤学组织，在全州22个不同的地点拥有32名内科、外科和放射肿瘤学家的网络。CCOP将与全州的本地从业者建立新的联盟，通过与NCCTG、ECOG、NSABP、GOG和RTOG等多个合作小组的联合，实现患者转介的持续增长，并增加NCI临床试验的可用性。其次，研究护士将在多个地点对临床试验的潜在参与者进行病历筛选。两个主要研究中心各有一名研究护士将单独负责启动各自地区的预防和癌症控制研究。以前在启动重大预防试验(BCPT和PCPT)方面的经验使许多社区资源得到认可，这些资源将得到扩大。第三，农村社区的多个CCA卫星办事处提供以前没有的当地癌症护理服务，以及获得NCI临床试验和预防/控制研究的机会。CCA医生和工作人员的集体资源和专业知识在农村社区通常没有的高质量癌症和治疗选择方面提供了许多好处。第四，CCOP将实施一个连接所有地点的计算机网络和一个电子病历，这将改善疾病管理，并提供以前无法获得的成本效益和患者结果数据。对这一数据的分析将有望证明参与临床试验对主要保险和管理保健提供者的好处。

The specific aim of the Sooner State CCOP is to provide the communities throughout the state with access to NCI-approved clinical trials which encompass cancer treatment and cancer control studies. Long-term objectives include: 1) Increasing the availability of NCI-approved clinical trials to the substantial underserved rural and minority populations in the state; 2) Expanding the involvement of community physicians in cancer prevention and cancer control projects; 4) Increasing patient accrual to NCI clinical trials; 5) Measuring the impact that the availability of NCI clinical trials has on clinical outcomes in the state. First, the Sooner State CCOP is a single component, Cancer Care Associates, Inc (CCA), a private practice oncology group with a statewide network of 32 medical, surgical, and radiation oncologists at 22 separate locations throughout the state. The CCOP will create new alliances with location practitioners statewide resulting in continued growth in patient referrals and increased availability of NCI clinical trials through association with multiple cooperative groups: NCCTG, ECOG, NSABP, GOG, and RTOG. Second, research nurses will implement screening of medical records at multiple sites for potential participants in clinical trials. A research nurse at each of the two primary research hubs will be responsible solely for activation of prevention and cancer control studies their respective regions. Previous experience in activating major prevention trials (BCPT and PCPT) led to the endorsement of numerous community resources which will be expanded. Third, multiple CCA satellite offices in rural communities provide local cancer care services not previously available, as well as access to NCI clinical trials and prevention/control studies. The collective resources and expertise of CCA physicians and staff provides numerous benefits in quality cancer and treatment options not usually available in rural communities. Fourth, the CCOP will implement a computer network connecting all sites and an electronic medical record which will improve disease management and provide data on cost effectiveness and patient outcomes previous impossible to obtain. Analysis of this data will hopefully demonstrate the benefits of clinical trials participation to major insurance and managed care providers.